Nymox Pharmaceutical Corp (NASDAQ:NYMX)
| CAPS Rating |
|
|---|---|
| Open | $8.60 |
| Previous Close | $8.60 |
| Daily Range | $8.60 - $8.65 |
| 52-Week Range | $6.00 - $9.89 |
| Market Cap | $280.56M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 56,564 |
| Average Daily Volume | 0 |
NYMX
VS S&P 500 (SPY)
How do you think NYMX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NYMX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NYMX News and Commentary
- The 10 Most-Watched Diagnostic Substances Stocks – The Motley Fool
- Why OraSure Technologies May Be About to Take Off – The Motley Fool
- Whoa! What Just Happened to My Stock? – The Motley Fool
- Analyst Calls: ADI, BKS, CMG, CRM, DANG, DLTR, FDO, LLTC, NFLX, X ... – BloggingStocks
- 3 Stocks Shaking the Market – The Motley Fool
- Hidden Stocks for High Returns – The Motley Fool
- 3 Stocks Shaking the Market – The Motley Fool
- Nymox Pharma Sees Positive Data On Prostate Drug – SmartMoney
- 3 Stocks Shaking the Market – The Motley Fool
- Low-Profile Stocks for High Returns – The Motley Fool
- The Stocks the Funds Are Buying – The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
RSS Headlines
Fool UK
